title: Chronic use of metamizole: not so safe after all?
abstract: Metamizole can be used in both short- and long-term pain relief therapies and has a relatively favourable safety profile compared with classic NSAIDs. Metamizole is also infamous because of its potential fatal adverse drug reaction, agranulocytosis. Although this risk varies, it is estimated to occur in less than one million metamizole prescriptions. We describe a case of a 68-year-old patient who developed leukopenia after using metamizole.
authors.affiliation: Department of Gastroenetrology, Jeroen Bosch Hospital, Den Bosch, the Netherlands.
authors.forename: F E R
authors.initials: FE
authors.lastname: Vuik
authors.forename: P
authors.initials: P
authors.lastname: Koehestanie
authors.forename: A H E
authors.initials: AH
authors.lastname: Herbers
authors.forename: J S
authors.initials: JS
authors.lastname: Terhaar Sive Droste
mesh_terms: D000368:Aged; D000380:Agranulocytosis / Q000139:chemically induced*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D004177:Dipyrone / Q000009:adverse effects*; D006801:Humans; D008297:Male; D013997:Time Factors
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D004177:Dipyrone